Key facts
- This page summarizes UBS Group AG's Form 4/A - Amendment filing for ENDRA Life Sciences Inc. (NDRA).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 05 Sep 2024, 15:28.
UBS Group AG - 27 Aug 2024 Form 4/A - Amendment Insider Report for ENDRA Life Sciences Inc. (NDRA)
- Reporting relationship
- Market maker/broker-dealer
- Issuer ticker
- NDRA
- Reported as of
- 27 Aug 2024
- Net transaction value
- $0
- SEC form
- 4/A - Amendment
- Accepted by SEC
- 05 Sep 2024, 15:28:10 UTC
- Original report date
- 29 Aug 2024
- Prior SEC filing
- 10 Jul 2024
- Next SEC filing
- 24 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- Andrew Johnson
Source evidence
Original filing metadata and source links for verification.
6 source fields
Reporting owner
1 detail
Key filing fact
UBS Group AG filed Form 4/A - Amendment for ENDRA Life Sciences Inc. (NDRA) on 05 Sep 2024.
Change
- Previous filing in this sequence was filed on 10 Jul 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NDRA
transaction
Common Stock
Purchase
- Transaction value
- $0
- Shares
- 0
- Change %
- 0%
- Price
- $0.000000*
- Shares after
- 146,012
- Date
- 27 Aug 2024
- Ownership
- By Subsidiary
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
UBS Group AG is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
This Statement is filed jointly by UBS Group AG for the benefit and on behalf of UBS Securities LLC and UBS Financial Services Inc., a wholly owned subsidiary of UBS Group.
Footnote F2
This Form 4 Amendment is being filed to correct and replace the original Form 4 filed on August 29, 2024. Subsequent to the date of first filing, the Reporting Person confirmed directly with the Issuer that, due to certain warrant exercises effected on August 27, 2024, the total outstanding common shares issued by ENDRA Life Sciences as of August 27, 2024 was 16,932,593 shares. When taking the revised share count into consideration, the Reporting Person determined it never beneficially owned more than 10% of ENDRA shares. Therefore the Form 4 previously filed by the Reporting Person was erroneous and unnecessary